within Pharmacolibrary.Drugs.ATC.B;

model B03BB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.0034,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B03BB01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Folic acid (vitamin B9) is a water-soluble B vitamin used for the prevention and treatment of folate deficiency, including in conditions such as anemia, during pregnancy to prevent neural tube defects, and in certain methotrexate toxicities. It is widely available as an oral supplement and approved for use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose of folic acid.</p><h4>References</h4><ol><li><p>Meng, F, et al., &amp; Zhang, J (2019). Folic acid and its metabolite codetermination for pharmacokinetics with circadian rhythms and evaluation of oral bioavailability. <i>The Journal of pharmacy and pharmacology</i> 71(11) 1645–1654. DOI:<a href=\"https://doi.org/10.1111/jphp.13155\">10.1111/jphp.13155</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31435940/\">https://pubmed.ncbi.nlm.nih.gov/31435940</a></p></li><li><p>Zhu, Q, et al., &amp; Qi, J (2021). Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. <i>Acta pharmaceutica Sinica. B</i> 11(8) 2416–2448. DOI:<a href=\"https://doi.org/10.1016/j.apsb.2021.04.001\">10.1016/j.apsb.2021.04.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34522593/\">https://pubmed.ncbi.nlm.nih.gov/34522593</a></p></li><li><p>Croze, ML, &amp; Soulage, CO (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases. <i>Biochimie</i> 95(10) 1811–1827. DOI:<a href=\"https://doi.org/10.1016/j.biochi.2013.05.011\">10.1016/j.biochi.2013.05.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23764390/\">https://pubmed.ncbi.nlm.nih.gov/23764390</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B03BB01;
